Sanofi has agreed to acquire Dynavax Technologies Corporation, adding an approved adult hepatitis B vaccine and a shingles vaccine candidate to its portfolio. The transaction strengthens Sanofi’s adult immunisation strategy at a time of persistent unmet vaccination needs.
Sanofi acquisition of Dynavax strengthens adult immunisation focus
The agreement brings Dynavax’s marketed hepatitis B vaccine, HEPLISAV-B, into Sanofi’s vaccines business. In addition, the acquisition includes a shingles vaccine candidate currently in early-stage clinical development.
Sanofi stated that the deal aligns with its strategy to expand adult immunisation offerings by combining Dynavax’s vaccine assets with Sanofi’s global development and commercial infrastructure.
HEPLISAV-B adds approved hepatitis B protection
HEPLISAV-B is approved for adult use and is currently marketed in the United States. Importantly, the vaccine is administered as a two-dose regimen over one month, compared with three-dose schedules used by other hepatitis B vaccines.
As a result, the product is positioned to address gaps in adult hepatitis B vaccination, particularly among populations that remain unvaccinated or under-vaccinated.
Shingles candidate and pipeline assets included
The transaction also includes Dynavax’s shingles vaccine candidate, Z-1018, which is in phase 1/2 clinical development. Meanwhile, additional early-stage vaccine pipeline programmes will transfer to Sanofi as part of the agreement.
Hepatitis B and shingles continue to represent significant public health challenges, particularly among older adults and immunocompromised populations.
Transaction terms and expected timeline
Under the merger agreement, Sanofi will acquire all outstanding Dynavax shares for USD 15.50 per share in cash, representing an equity value of approximately USD 2.2 billion.
The transaction has been approved by the Dynavax board and is expected to close in the first quarter of 2026, subject to regulatory approvals and customary closing conditions.
More information about Sanofi is available on its official website at sanofi.com. Details on Dynavax can be found at dynavax.com.
For related coverage, visit the Pharmaceuticals section of H2O Global News.
